Source: Fox News
Summary
Research suggests that glucagon-like peptide-1 (GLP-1) medications, such as Ozempic and Wegovy, may be associated with a lower risk of cancer diagnoses and recurrence, particularly breast cancer. Dr. Loren Rourke, a breast cancer surgeon, notes that the evidence is observational and cannot prove that the drugs reduce cancer risk. However, she suggests that GLP-1s may aid in cancer prevention by promoting weight loss and reducing chronic inflammation.
Our Reading
The advice sounds familiar.
GLP-1 medications have been shown to have benefits beyond diabetes and obesity treatment, including a potential role in cancer prevention. However, the evidence is still observational, and more research is needed to prove a direct cause. Researchers are now starting to conduct randomized controlled trials to further investigate the relationship between GLP-1s and cancer prevention.
As we wait for more conclusive evidence, it’s interesting to note that GLP-1s have been shown to decrease estrogen production associated with excess body fat, which could potentially lower the risk of breast cancer. Additionally, GLP-1s have anti-inflammatory properties, which could also contribute to their potential cancer-preventing effects.
It’s also worth noting that GLP-1s have been shown to have a secondary benefit of weight loss, which could be beneficial for post-menopausal women who are struggling with weight gain. However, it’s essential to have a one-on-one conversation with a doctor before starting GLP-1s.
The familiar pattern of emerging research, observational evidence, and the need for further studies is a common theme in the world of health and medicine.
Author: Evan Null
